H.C. Wainwright analyst Michael King maintained a Buy rating on Intellia Therapeutics (NTLA – Research Report) today and set a price target of $182.00. The company’s shares closed last Thursday at $94.78.
According to TipRanks.com, King is a 4-star analyst with an average return of 13.1% and a 45.5% success rate. King covers the Healthcare sector, focusing on stocks such as Sonnet BioTherapeutics Holdings, Werewolf Therapeutics, and Compass Therapeutics.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Intellia Therapeutics with a $158.88 average price target, which is a 67.8% upside from current levels. In a report issued on January 31, Cowen & Co. also initiated coverage with a Buy rating on the stock.
The company has a one-year high of $202.73 and a one-year low of $43.86. Currently, Intellia Therapeutics has an average volume of 889.6K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Intellia Therapeutics, Inc. engages in the development of gene editing-based therapies. It provides scientific expertise, clinical development, and intellectual property position to unlock broad therapeutic applications of CRISPR or Cas9 genome editing and develop a potential new drug class. The company was founded by Andrew May, Luciano Marraffini, Rodolphe Barrangou, Nessan Bermingham, Rachel Haurwitz, Erik Sontheimer, Jennifer Doudna, and Derrick Rossi in May 2014 and is headquartered in Cambridge, MA.
Read More on NTLA:
- Colliers Securities Maintains Their Buy Rating on Alpine Income Property Trust Inc (PINE)
- Baader Bank Keeps a Buy Rating on Linde (LIN)
- Pixelworks (PXLW) Receives a Buy from Colliers Securities
- Maxim Group Thinks Viking Therapeutics’ Stock is Going to Recover
- What Made Needham Upgrade Monolithic Power’s Stock?